Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1404-1409

  May, Larissa ^a   Klein, Eili Y ^b,c   Rothman, Richard E ^b   Laxminarayan, Ramanan ^c,d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Center for Disease Dynamics Economics and Policy   (United States)

^d PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; HEALTH CARE; HOSPITAL PATIENT; HUMAN; MULTIDRUG RESISTANCE; PRESCRIPTION; PRIORITY JOURNAL; STAPHYLOCOCCUS CAPRAE; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS SAPROPHYTICUS; STAPHYLOCOCCUS SCHLEIFERI; TREND STUDY; UNITED STATES;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LEVOFLOXACIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; UNITED STATES;

EID: 84896847880     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01908-13     Document Type: Article

References (40)

1. Ahlstrand E, Persson L, Tidefelt U, Söderquist B. 2012. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur. J. Clin. Microbiol. Infect. Dis. 31:1679-1687. http://dx.doi.org/10.1007/s10096-011-1493-6.
2. Beekmann SE, Diekema DJ, Doern GV. 2005. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect. Control Hosp. Epidemiol. 26:559-566. http://dx.doi.org/10.1086/502584. (Pubitemid 40896146)
3. Piette A, Verschraegen G. 2009. Role of coagulase-negative staphylococci in human disease. Vet. Microbiol. 134:45-54. http://dx.doi.org/10.1016/j.vetmic. 2008.09.009.
4. Otto M. 2012. Molecular basis of Staphylococcus epidermidis infections. Semin. Immunopathol. 34:201-214. http://dx.doi.org/10.1007/s00281-011-0296-2.
5. Anday E, Talbot G. 1985. Coagulase-negative Staphylococcus bacteremia - a rising threat in the newborn infant. Ann. Clin. Lab. Sci. 15:246-251. (Pubitemid 15123093)
6. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, Wilson WR, Steckelberg JM, Baddour LM. 2012. Clinical features and outcomes of cardiovascular implantable electronic device infections due to staphylococcal species. Am. J. Cardiol. 110:1143-1149. http://dx.doi.org/10.1016/j.amjcard. 2012.05.052.
7. Otto M. 2013. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. Annu. Rev. Med. 64:175-188. http://dx.doi.org/10.1146/annurev-med-042711-140023.
8. Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R, Beach M. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:S114-S132. http://dx.doi.org/10.1086/320184. (Pubitemid 32424266)
9. Rogers KL, Fey PD, Rupp ME. 2009. Coagulase-negative staphylococcal infections. Infect. Dis. Clin. North Am. 23:73-98. http://dx.doi.org/10.1016/j. idc.2008.10.001.
10. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244. http://dx.doi.org/10.1086/520192. (Pubitemid 29380177)
11. Jones RN. 2003. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care. Med. 24:121-134. http://dx.doi.org/10.1055/s-2003-37923.
12. Pfaller M, Jones R, Doern G, Sader H, Kugler K, Beach M. 1999. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from theSENTRYAntimicrobial Surveillance Program. SENTRY Participants Group. Diagn. Microbiol. Infect. Dis. 33:283-297. http://dx.doi.org/10.1016/S0732-8893(98)00149-7. (Pubitemid 29142369)
13. Jones ME, Mayfield DC, Thornsberry C, Karlowsky JA, Sahm DF, Peterson D. 2002. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob. Agents Chemother. 46:3104-3105. http://dx.doi.org/10.1128/AAC.46.9.3104-3105.2002.
14. Sahm DF, Marsilio MK, Piazza G. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database-U. S. A. Clin. Infect. Dis. 29:259-263. http://dx.doi.org/10. 1086/520195. (Pubitemid 29380180)
15. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. 2013. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect. Control Hosp. Epidemiol. 34:259-268. http://dx.doi.org/10.1086/669523.
16. Hoffmann MS, Eber MR, Laxminarayan R. 2010. Increasing resistance of acinetobacter species to imipenem in United States hospitals, 1999-2006. Infect. Control Hosp. Epidemiol. 31:196-197. http://dx.doi.org/10.1086/650379.
17. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688. http://dx.doi.org/10.1128/AAC.47.5.1681-1688.2003. (Pubitemid 36548554)
18. Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13:1840-1846. http://dx.doi.org/10.3201/eid1312.070629. (Pubitemid 350248484)
19. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. 2005. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg. Infect. Dis. 11:868-872. http://dx.doi.org/10.3201/eid1106. 040831. (Pubitemid 40720847)
20. Styers D, Sheehan DJ, Hogan P, Sahm DF. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5:2. http://dx.doi.org/10.1186/1476-0711-5-2.
21. Sun L, Klein EY, Laxminarayan R. 2012. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin. Infect. Dis. 55:687-694. http://dx.doi.org/10.1093/cid/cis509.
22. Hooper DC. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl 2):S24 -S28. http://dx.doi.org/10. 1086/314056.
23. Garrison MW. 2003. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 52:503-506. http://dx.doi.org/10.1093/jac/dkg380. (Pubitemid 37120737)
24. Hidalgo M, Reyes J, Cárdenas AM, Díaz L, Rincón S, Vanegas N, Díaz PL, Castañeda E, Arias CA. 2008. Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci. Biomédica. 28:284-294.(In Spanish.)
25. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW, Jr. 2006. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch. Ophthalmol. 124:479-483. http://dx.doi.org/10.1001/archopht.124.4.479.
26. Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17:857-872. http://dx.doi.org/10.1002/(SICI)1097-0258(19980430)17:8〈857:: AID-SIM777〉3.0.CO;2-E.
27. Mendes RE, Deshpande LM, Costello AJ, Farrell DJ. 2012. Molecular epidemiology of Staphylococcus epidermidis clinical isolates from US hospitals. Antimicrob. Agents Chemother. 56:4656-4661. http://dx.doi.org/10.1128/AAC.00279- 12.
28. Dimitriou G, Fouzas S, Giormezis N, Giannakopoulos I, Tzifas S, Foka A, Anastassiou D, Spiliopoulou I, Mantagos S. 2011. Clinical and microbiological profile of persistent coagulase-negative staphylococcal bacteraemia in neonates. Clin. Microbiol. Infect. 17:1684-1690. http://dx.doi.org/10.1111/j.1469-0691. 2011.03489.x.
29. Bathoorn E, Hetem DJ, Alphenaar J, Kusters JG, Bonten MJ. 2012. Emergence of high-level mupirocin resistance in coagulase-negative staphylococci associated with increased short-term mupirocin use. J. Clin. Microbiol. 50:2947-2950. http://dx.doi.org/10.1128/JCM.00302-12.
30. Robicsek A, Jacoby GA, Hooper DC. 2006. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6:629-640. http://dx.doi.org/10.1016/S1473-3099(06)70599-0. (Pubitemid 44427732)
31. Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual Á. 2011. Plasmid-mediated quinolone resistance: an update. J. Infect. Chemother. 17:149 -182. http://dx.doi.org/10.1007/s10156-010-0120-2.
32. Otto M. 2013. Coagulase-negative staphylococci as reservoirs of genes facilitating MRSA infection. Bioessays 35:4-11. http://dx.doi.org/10.1002/bies. 201200112.
33. Tulinski P, Fluit AC, Wagenaar JA, Mevius D, van de Vijver L, Duim B. 2012. Methicillin-resistant coagulase-negative staphylococci on pig farms as a reservoir of heterogeneous staphylococcal cassette chromosome mec elements. Appl. Environ. Microbiol. 78:299-304. http://dx.doi.org/10.1128/AEM.05594-11.
34. Barbier F, Ruppé E, Hernandez D, Lebeaux D, Francois P, Felix B, Desprez A, Maiga A, Woerther P-L, Gaillard K. 2010. Methicillin-resistant coagulase-negative staphylococci in the community: high homology of SCCmec IVa between Staphylococcus epidermidis and major clones of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 202: 270-281. http://dx.doi.org/10.1086/ 653483.
35. Klein EY, Sun L, Smith DL, Laxminarayan R. 2013. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: A national observational study. Am. J. Epidemiol. 177:666-674. http://dx.doi.org/10.1093/aje/kws273.
36. Blondeau JM. 1999. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 21:3-40. http://dx.doi.org/10.1016/ S0149-2918(00)88266-1. (Pubitemid 29106688)
37. Appelbaum PC, Hunter PA. 2000. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 16:5-15. http://dx.doi.org/10.1016/S0924-8579(00)00192-8. (Pubitemid 30665419)
38. Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc JL, Lapeyre-Mestre M, Sommet A. 2010. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J. Antimicrob. Chemother. 65: 2650-2657. http://dx.doi.org/10.1093/jac/dkq351.
39. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. 2009. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J. Antimicrob. Chemother. 64:169-174. http://dx.doi.org/10. 1093/jac/dkp162.
40. Rahkonen M, Luttinen S, Koskela M, Hautala T. 2012. True bacteremias caused by coagulase negative Staphylococcus are difficult to distinguish from blood culture contaminants. Eur. J. Clin. Microbiol. Infect. Dis. 31:2441-2446. http://dx.doi.org/10.1007/s10096-012-1607-9.